Nuclidium AG, a pioneering biotech firm operating out of Basel and Munich, has raised an impressive €84 million (approximately $98.5 million USD) in a Series B funding round. The round was led by Kurma Growth Opportunities Fund and joined by Angelini Ventures, Wellington Partners, and Neva SGR, with participation from DeepTech & Climate Fonds, Bayern Kapital, Eurazeo, VIVES Partners, NRW.BANK, and HighLight Capital.

This milestone signals strong investor confidence in Nuclidium’s copper-based radiotheranostic platform and its potential to reshape cancer diagnosis and treatment globally.

A New Era in Radiotheranostics

Nuclidium’s CuTrace™ platform is a next-generation radiotheranostic technology that combines Copper-61 for PET-based diagnostics and Copper-67 for targeted radiotherapy. This dual-use of copper isotopes enables physicians to both detect and treat solid tumors using a single molecular platform - an advancement that could drive significant gains in clinical precision, cost efficiency, and scalability.

Targeting cancers such as prostate, breast, and neuroendocrine tumors, CuTrace™ integrates seamlessly into the existing clinical infrastructure. Unlike traditional radiopharmaceuticals that depend on short-lived isotopes and complex production logistics, Nuclidium’s copper isotopes have longer half-lives and can be synthesized using widely available cyclotron technology.

Solving Access and Scale in Nuclear Medicine

One of the major bottlenecks in the radiotheranostics field has been supply chain fragility. Many platforms depend on isotopes that degrade within hours, requiring tight coordination between nuclear reactors and hospitals. Nuclidium sidesteps this entirely with isotopes that remain stable longer and can be manufactured closer to the point of care, dramatically expanding treatment availability.

This model positions Nuclidium not just as a biotech innovator, but as an infrastructure enabler - lowering the operational barrier for hospitals and research centers worldwide to adopt next-gen nuclear medicine tools.

Many in radiopharma had accepted those logistical and technical constraints as the cost of doing business. Short-lived isotopes, complex manufacturing, and narrow distribution pipelines were simply part of the landscape. But Nuclidium’s team - led by founder and CEO Leila Jaafar - refused to accept those trade-offs as permanent. By focusing on copper isotopes that offered longer shelf life and broader compatibility with existing infrastructure, they uncovered a path forward that others had overlooked.

This mindset - of refusing to settle for industry "norms" - reveals a profound strategy lesson for entrepreneurs: the most transformative opportunities often lie in challenging the invisible assumptions everyone else has learned to live with. Nuclidium didn’t just find a better way to deliver radiotherapy - they redefined the rules of access, scale, and safety in nuclear medicine. Founders in any vertical should take note: innovation often begins where resignation ends.

Clinical Trials and Pipeline Acceleration

With fresh capital in hand, Nuclidium is accelerating its clinical programs, particularly around 61Cu-NuriPro™, a diagnostic tracer that has already shown superior performance in identifying prostate cancer lesions - up to 50% more accurately than traditional tracers.

The company is also advancing therapeutic programs focused on high tumor-selectivity with minimal systemic toxicity, a key to improving outcomes without compromising patients' quality of life. These programs are expected to enter later-stage clinical testing over the next 12 to 18 months.

Infrastructure and Global Expansion

Beyond R&D, the Series B will support strategic expansion of Nuclidium’s GMP manufacturing network, enabling the company to serve hospitals across Europe and North America. This includes investments in cyclotron partnerships, talent acquisition, and regulatory collaboration to streamline approval pathways.

As the company scales, it plans to build out an ecosystem of academic institutions, healthcare providers, and pharmaceutical partners - all committed to pushing the boundaries of copper-based oncology innovation.

A Blueprint for Precision Oncology

Nuclidium’s success marks more than a funding win - it represents a shift in how radiopharmaceuticals are conceptualized, produced, and delivered. By uniting diagnostic and therapeutic functions in a scalable, infrastructure-friendly package, the company is helping unlock the full promise of precision oncology for a global patient population.

In doing so, Nuclidium is setting a precedent that deep tech startups across verticals can follow: challenge the assumptions others take for granted, and you may just redefine an entire category.